ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer (NCT06328738)
A Phase 1a/1b Study of ELVN-002 Combined With Trastuzumab in Advanced Stage HER2+ Solid Tumors, and ELVN-002 Combined With Trastuzumab and Chemotherapy in Advanced Stage HER2+ Colorectal Cancer and Breast Cancer
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to determine the safety, tolerability, and recommended dose of ELVN-002 in combination with trastuzumab in participants with advanced-stage HER2-positive tumors and in combination with trastuzumab, and chemotherapy in participants with advanced-stage HER2-positive colorectal cancer and breast cancer.
Who can join: Review the eligibility criteria below.
Location: BRCR Medical Center Inc. — Plantation, Florida
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (31 Sites)
Showing the first 25 of 31 sites.
- BRCR Medical Center Inc. — Plantation, Florida
- Washington University — St Louis, Missouri
- NEXT Virginia — Fairfax, Virginia
- Cliniques Universitaires Saint-Luc — Brussels,
- CHU de Liège — Liège,
- GZA Ziekenhuizen - Campus Sint-Augustinus — Wilrijk,
- Institut du Cancer de Montpellier - Val D'Aurelle — Montpellier,
- CHU de Poitiers — Poitiers,
- Institut de Cancérologie de l'Ouest — Saint-Herblain,
- Institut de Cancérologie Strasbourg Europe — Strasbourg,
- Azienda Ospedaliero-Universitaria Renato Dulbecco — Catanzaro,
- Istituto Europeo di Oncologia — Milan,
- Fondazione IRCCS San Gerardo dei Tintori — Monza,
- Azienda Ospedaliero Universitaria Pisana — Pisa,
- Azienda USL IRCCS di Reggio Emilia — Reggio Emilia,
- Fondazione Policlinico A. Gemelli IRCCS — Rome,
- Radboud UMC — Nijmegen,
- CHA Bundang Medical Center — Seongnam-si,
- Severance Hospital, Yonsei University Health System — Seoul,
- Asan Medical Center — Seoul,
- Seoul National University Hospital — Soeul,
- The Catholic University of Korea, St. Vincent's Hospital — Suwon,
- NEXT Oncology-Hospital Quironsalud Barcelona — Barcelona,
- START Barcelona_HM Nou Delfos — Barcelona,
- Hospital Universitari Dexeus - Grupo Quironsalud — Barcelona,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in HER2-positive Breast Cancer
- Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease — Tampa, Florida
- Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP] — Los Angeles, California
- PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer — Boston, Massachusetts
- A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer — Mobile, Alabama
- A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer — Stamford, Connecticut
Explore by condition: All HER2-positive Breast Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.